IP Library › Granted Patent US 11,227,685
Granted Patent B2
US 11,227,685 · App. 16/848,458 · Granted Jan 18, 2022

System and method for laboratory-based authorization of genetic testing

Inventors: Rob Todd (Doylestown, PA); Jerry Wrobel (Aurora, OH); John Pigott (Sylvania, OH)
G16H40/20C12Q1/6869G06F16/245G06F40/205G06Q10/10G06Q20/42G06Q30/016G06Q40/02G06Q40/08G16B35/20G16H10/40G16H10/60G16H70/40H04L63/0428
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,227,685
App. No.
16/848,458
Granted
Jan 18, 2022
Kind
B2
Abstract

System and methods for providing laboratory-based authorization of genetic testing are disclosed. An order for genetic testing is received from an electronic health record (“EHR”) system at a laboratory information system (“LIS”). A prior authorization request is automatically generated at the LIS from data parsed from the order and retrieved from the EHR and sent to a prior authorization provider. If a patient responsibility amount returned to the LIS is below a threshold, testing proceeds. If the patient responsibility amount is above the threshold, an electronic call center request is generated and the patient is contacted to obtain payment. If a billing consent is not obtained, the specimen for the order is destroyed.

Claims (26)

1. A system for laboratory-based authorization for genetic based medication efficacy testing, said system comprising:

a number of healthcare provider systems, each comprising an electronic health record (“EHR”) system comprising diagnoses and active medications for a number of patients;

a laboratory system comprising a laboratory information system (“LIS”) in electronic communication with each of the number of healthcare provider systems and the respective EHR systems and genetic sequencing devices in electronic communication with the LIS, wherein said LIS comprises an automated pre-approval request engine;

a database in electronic communication with the LIS comprising medications known to be wholly or partially ineffective in persons having particular genetic markers;

a prior authorization provider system in electronic communication with the LIS;

a call center system in electronic communication with the LIS; and

a payment processing system in electronic communication with the call center system;

wherein said automated pre-approval request engine is configured to, for each of a number of received electronic HL7 orders:

query the EHR associated with an ordering one of the healthcare provider systems to retrieve active medications and diagnoses associated with a patient identifier provided in the respective electronic HL7 order;

automatically parse the patient identifier, insurance policy information, and ordered testing from the respective electronic HL7 order and the diagnoses and the active medications from the EHR to generate a prior authorization request;

electronically transmit, from the LIS to the prior authorization provider, the prior authorization request;

receive, from the prior authorization provider at the LIS, a reference number and patient responsibility amount for the prior authorization request;

for each of the number of received electronic HL7 orders having a patient responsibility amount below a predetermined threshold:

instructing, by way of the LIS, one of the genetic sequencing devices to perform the ordered testing on a specimen received for the respective electronic HL7 order to determine the patient's genetic makeup;

query the database to retrieve medications known to be wholly or partially ineffective in persons having the same genetic makeup as the patient;

determine, at the LIS, if one or more of the active medications match the retrieved medications;

integrate testing results into the EHR of the healthcare provider system by flagging ineffective medications as allergies;

for each of the number of received electronic HL7 orders having a patient responsibility amount above a predetermined threshold:

transmit an encrypted email comprising patient contact information and the patient responsibility amount from the LIS to the call center system;

contact the patient contact information by way of the call center system to request payment for the patient responsibility amount;

where payment is not received from the patient, provide a notification to the LIS to destroy the specimen for the respective electronic HL7 order; and

wherein payment is received:

instructing, by way of the LIS, one of the genetic sequencing devices to perform the ordered testing on the specimen received for the respective electronic HL7 order to determine the patient's genetic makeup;

query the database to retrieve medications known to be wholly or partially ineffective in persons having the same genetic makeup as the patient;

determine, at the LIS, if one or more of the active medications match the retrieved medications; and

integrate testing results into the EHR of the healthcare provider system by flagging ineffective medications as allergies.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 14, 2020
From: TODD, ROB; WROBEL, JERRY; PIGOTT, JOHN
To: XACT LABORATORIES, LLC
Reel/Frame 052394/0552 →
Continuity (5)
Continuation In Part 16674189 · Nov 5, 2019
Continuation In Part 16441597 · Jun 14, 2019
Provisional Application 62773424 · Nov 30, 2018
Provisional Application 62685479 · Jun 15, 2018
Related Publication 20200243190A1 · Jul 30, 2020